Fluorescently-labeled ligands are useful pharmacological research tools for studying receptor localization, trafficking and signaling processes via fluorescence imaging. They are also employed in fluorescent binding assays. This study is centered on the design, synthesis and pharmacological evaluation of fluorescent probes for the opioid receptors, for which relatively few non-peptidic fluorescent probes currently exist. The known µ-opioid receptor (MOR) partial agonist, buprenorphine, was structurally elaborated to include an amidoalkylamine linker moiety that was coupled with a range of fluorophores to afford new fluorescent probes. All compounds proved to be selective MOR antagonists. Confocal fluorescence microscopy studies revealed that the probe incorporating a sulfonated cyanine-5 fluorophore (3) was the most appropriate for imaging studies.
 RESULTS AND DISCUSSION Fluorescent ligand design and synthesis. A range of ligand design options were considered in which the linker and fluorophore could be attached to different positions of a morphinan core. Linking from the tertiary amine seemed chemically feasible (e.g. via N-demethylation and alkylation), however the OR crystal structures 1, [7] [8] [9] suggested that this amine is buried deep within the active site and would therefore have limited tolerance to groups appended at this position. Some substitutions at this position can convert agonists to antagonists, as evidenced by naltrexone. Linking from the 3-position of the phenol moiety was another potential strategy. However, even simple methylation at this position (codeine) reduces binding affinity by approximately 200-fold. 33 A more interesting possibility for linker attachment was the 7-position of the morphinan scaffold, via a Diels-Alder reaction, since this could lead to an increase in affinity, as demonstrated by ligands such as etorphine and buprenorphine. 34 Previous work conducted on the development of fluorescently labeled OR ligands [25] [26] [27] [28] as well as bivalent ligands [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] indicates that the C-ring of the morphinan scaffold (which incorporates the 6-and 7-positions) is generally reasonably tolerant of substitution. With these factors in mind, the synthesis and biological evaluation of three different congeners ( Figure 2 ) featuring a linker attached via the 7position were pursued. In two of these structures (9 and 11) the linker was attached via a Diels-Alder reaction involving the C-ring diene of oripavine and methyl acrylate. Subsequent saponification and amide coupling incorporated the full linker unit (amide congeners). The third congener was derived from the Diels-Alder reaction of oripavine with a fully formed linker unit that possessed a terminal Nsubstituted maleimide group (imide congener). Literature precedence suggests that conjugation of a maleimide group retains affinity when connected in this position, and alkyl chains are also tolerated. 45, 46 Amide congeners. Scheme 1 details the synthetic pathway used to access the amide derivatives, with oripavine as the starting molecule. Following protection of phenol 5 to its corresponding tertbutyldimethylsilyl (TBS) ether (6) , a Diels-Alder reaction between the latter and methyl acrylate, afforded ester 7. 47 Compared to dienophiles such as methyl vinyl ketone, the ester presents a weaker electron-withdrawing group compared to the ketone, therefore requiring more forcing conditions to achieve complete conversion to the Diels-Alder product. This was achieved through irradiating the sample for three hours at 130 o C in a microwave in neat methyl acrylate. Compound 7 was isolated in good yield (69%) following recrystallization from minimal hot methanol, which was necessary to remove a small amount of the 8-regioisomer byproduct. Saponification of methyl ester 7 with lithium hydroxide and subsequent amide coupling with tertbutyl (6-aminohexyl)carbamate using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl) and N-hydroxybenzotriazole (HOBt) afforded Boc-protected congener 8 in a respectable yield (44%) with > 95% purity according to HPLC. An "H-cube" hydrogenation system was then employed to reduce the olefin in the next step (small scales of 500 mg or less). This occurred cleanly within two hours to produce 10 in high yield (86%). Acidolytic Boc group removal was performed on both the unreduced (8) and reduced (10) versions of the protected congeners to give compounds 9 and Imide congener. The synthetic route for these derivatives commenced with synthesis of a maleimide-bearing linker group though reaction of N-(ethoxycarbonyl)maleimide 48 with mono-Bocprotected diaminohexane (Scheme 2). After one hour, 12 was obtained as a pure white solid in high yield (89%). This high yield was only achieved if fresh (no more than a week old) N-(ethoxycarbonyl)maleimide was used and if the amine was stirred in saturated NaHCO3 at 0 o C before adding in the maleimide. Compound 13 was synthesized via a Diels-Alder reaction between 12 and oripavine (Scheme 2).
This reaction required less forcing conditions compared to methyl acrylate as the maleimide group is a stronger dienophile. Additionally, as the maleimide is connected through both the 7 and 8 positions, no minor regioisomer byproducts were produced and hence purification was performed via silica chromatography.
Unfortunately, reducing the alkene moiety of these compounds proved problematic. Reaction conditions trialed in the H-cube included pressures as high as 20 bar (280 psi), yet no reduction took place, even after two hours. One possible explanation for this difficulty is that the bulkiness of the maleimide group hinders the olefin's approach to the palladium catalyst. Only the unreduced version of this congener was therefore tested, and it was assumed that enough information about the effect of the olefin on potency and affinity could be garnered from the amide congeners. Finally, acidolytic removal of the Boc protecting group of 13, followed by column chromatography to remove minor impurities, afforded congener 14 as its bis-HCl salt.
The different congeners were compared pharmacologically to assess which modifications were tolerated by the MOR and which, if any, retained the partial MOR selectivity of the parent molecule (vide infra). In all cases, the corresponding tert-butyloxycarbonyl (BOC) protected congeners were also evaluated in order to help assess if there was potential receptor tolerance for further chemical elaboration at the end of the linker unit. butanoic acid linker at one end and a methoxy "cap" at the other. Such alkoxy groups render tetrazines fluorescent. 51-54 Additionally, these groups ensure that no other group reacts with the tetrazine via nucleophilic substitution, in particular thiols and amines, which cause loss of tetrazine fluorescence. 51
Compound 15 was first reacted with excess methanol to replace one of the chloro groups with a methoxy substituent. 54 Following this, the remaining chloro group was substituted with 1,4-butanediol in low yield (19%) by adapting the method of Gong et al. 53 and employing NaH to deprotonate the alcohol reactant (substitution with 4-hydroxybutanoic acid was also trialed in an attempt to directly access 18, however this led to degradation of the tetrazine core). The low yield of 17 is thought to be due to partial degradation of the tetrazine by the reactive alkoxide, combined with the formation of byproducts resulting from 1,4-butanediol displacing both the methoxy and chloro groups of 16 or forming crosslinked species (an extra equivalent of the diol was added in an attempt to minimize double-deprotonation of the diol). The penultimate step involved oxidation of the terminal alcohol under mild conditions, employing a catalytic amount of chromium trioxide (1.2 mol%) and periodic acid as per the method of Zhao et al. 55 Finally, the carboxylic acid group of 18 was converted to the Nhydroxysuccinimide (NHS) ester using dicyclohexylcarbodiimide (DCC) as the coupling reagent. 1 The final step was to conjugate the fluorophores as per Scheme 4. The amide congener 11 was selected over the imide congener due to its higher binding affinity (vide infra) (note that the bis-TFA salt form of 11 (11b), rather than the bis-HCl salt (11a), was used for three of the probes). While BODIPY TM 630/650 and the tetrazine derivative were reacted as N-hydroxysuccinimide esters, 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) was used to couple the unactivated naphthalimide and sulfo-Cy5 derivatives to the congener. The naphthalimide probe 1 was isolated in reasonable yield (48%) via this method, however a guanidiunium byproduct was detected in significant amounts for the sulfo-Cy5 probe 3, formed as a result of the amine reacting directly with the coupling reagent. 56 The use of benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) as a coupling agent eliminated this problem, although 3 could still only be isolated in low yield (18%).
Conjugation of the BODIPY TM 630/650 and tetrazine fluorophores was performed using the reaction conditions set out by Middleton et al. 57 Purification of 2 required only preparative HPLC (32% yield), however for 4, an extra extraction step (1:3 IPA:CHCl3) was required to remove the DCU carried over from the previous step (18% yield). Firstly, the amide linker is generally better tolerated than the imide linker; three of the four compounds (8, 10 and 11) with amide linkers have a higher binding affinity than the imide congeners. The amide equivalent (8) of the protected, unreduced imide congener (13) displayed approximately 35-fold higher affinity for the ORs. One possible explanation for this is that the amide group is more flexible than the imide group and is thus able to rotate itself into a position where it can make more favorable hydrogenbonding interactions with surrounding residues, or minimize unfavorable steric interactions. The reduction of the olefin is associated with a 2-3-fold increase in OR affinity (10 vs. 8 and 11 vs. 9), which may again be due to increased flexibility. Finally, the Boc-protected congeners, 8, 10 and 13, exhibited approximately 26-, 49-and 8-fold higher OR affinity compared to the respective deprotected analogs, 9, 11 and 14. This indicates not only that the linker is well tolerated, but that it is sufficiently long that reasonably bulky groups can be attached to its terminus without disrupting binding. and MOR-overexpressing cells were also conducted, indicating that all congeners have no detectable agonist activity at this signaling pathway after 30 min (data not shown)). Assuming competitive binding, the affinities (pA2) of the fluorescent probes for the three receptor subtypes ( Table 2) were determined using the Gaddum-Schild equation as per Lane et al. 59 Each of the probes showed high affinity for the MOR, together with a strong preference for this OR subtype over KOR and DOR (selectivity ratios of 9-45 and > 200, respectively). The selectivity ratios for 2 and 4 indicate that they are amongst the most MOR-selective fluorescent opiate antagonists reported to date. [25] [26] [27] Imaging studies. The absorption and emission profiles of the synthesized probes ( Figure S23) were recorded using a FlexStation 3 plate reader in both hydrophilic (HEPES buffered saline solution, HBSS) and hydrophobic (dimethylsulfoxide, DMSO) environments at a concentration of 10 μM.
These solvents were used to represent the polar aqueous and comparatively non-polar ligand binding site environment within an OR, respectively. Such measurements were necessary to ensure that appropriate excitation wavelength and dichroic emission filters were used in the subsequent imaging experiments.
In general, all of the observed excitation and emission maxima (Table S1 ) closely matched those reported in the literature for the corresponding "free" fluorophore. 50, 60, 61 All probes experienced a significant decrease in emission intensity and, in most cases, a hypsochromic shift in maxima upon moving from DMSO to HBSS, which is particularly useful from the perspective of developing fluorescent displacement-style binding assays. Unfortunately, no signal could be detected for the tetrazine probe, 4, even at 100 μM, despite the fact that yellow fluorescence could be observed under long-wavelength UV irradiation (TLC lamp).
It was encouraging that the BODIPY TM 630/650 derivative (2) exhibited the highest MOR affinity (vide supra) as it has particularly favorable photophysical properties for imaging and assay applications. Most BODIPY fluorophores have high quantum yields, often approaching unity, and a high molar extinction coefficient (101,000 cm -1 M -1 ). 62 Probe 2 displayed bright fluorescence in a relatively non-polar environment (DMSO), but almost full quenching of fluorescence in an aqueous environment ( Figure S23 ), which would obviate the need for a washing step in a fluorescent displacement-style binding assay.
Single-time point confocal images of human embryonic kidney cells (HEK) stably expressing the human MOR-GFP fusion protein were captured after incubation with each of the probes (Figure 3 ).
The MOR was expressed with green fluorescent protein at its C-terminus so that the binding specificity of each probe could be assessed from the degree of co-localization of probe and GFP fluorescence.
The strong binding affinity and favorable photophysical properties of BODIPY TM 630/650 allowed probe 2 to be clearly imaged at relatively low concentration (5 nM). There was a high degree of colocalization of the probe with MOR-GFP and significant displacement of binding by the nonfluorescent antagonist, naloxone, providing strong evidence that binding is specifically to the MOR.
However, the fact that not all the fluorescent signal was lost upon incubation with a large excess of the unlabeled MOR-specific ligand indicates some degree of non-specific interaction of 2 with the cellular membrane ( Figure 3 ).
The concentration required to image binding of probe 3 (50 nM) was higher than that required for 2, consistent with its almost 10-fold lower affinity for the MOR. Unlike 2, this probe could be almost completely displaced using excess naloxone ( Figure 3 ), again indicating that it binds specifically to the MOR, but also that the use of a more hydrophilic sulfo-Cy5 fluorophore reduces non-specific interaction with the cellular membrane.
Displacement of 3 with naloxone was also accompanied by a large decrease in fluorescence intensity, consistent with the reduced fluorescence of this probe in an aqueous environment. It should be noted that no wash steps were performed in these imaging experiments, so the observed reductions in fluorescence were not simply due to a concentration gradient-driven re-equilibration process.
In the case of 1 and 4, no fluorescence was observed after incubating cells with the probes; hence their quantum yields appear to be inadequate for imaging purposes under the conditions employed here. Fluorescent binding assays. The imaging studies suggested that probes 2 and 3 may be suitable for use in a fluorescence-based competition binding assay as per Stoddart et al. 63 As a prelude to this, experiments were performed to establish an appropriate pre-incubation time ( Figure 4 ). To confirm that 3 was suitable for use in determining the affinity of unlabeled ligands, MOR receptor-expressing cells were co-incubated with 3 (50 nM) and increasing concentrations of either the MOR agonists, DAMGO and dermorphin, or the MOR antagonists, diprenorphine, naloxone, naltrexone and naloxonazine, with xanthine amine congener (XAC), an adenosine receptor antagonist included as a negative control. The affinity of each test compound (pKi, Table 3 ) was determined from the IC50 value obtained from the competition curve constructed by measuring the decrease in fluorescence intensity caused by the compound competing with 3 for the MOR ( Figure 5 ). For the antagonists, excellent agreement was found between the pKi values obtained from the automated confocal imaging and literature values derived from radioligand binding assays (Table 3 ).
In contrast, the pKi values obtained for the agonists were significantly lower than the literature values. [64] [65] [66] [67] However, it is of note that the literature values were obtained from radioligand binding assays using a titrated agonist ([ 3 H]DAMGO). As such, the affinities reported in literature represent the high-affinity G protein-coupled state of the receptor. As our fluorescent ligand competition binding assays were performed in whole cells, where the intracellular concentration of GDP is significantly higher than GTP, the receptor will exist predominantly in the low-affinity G protein uncoupled state state, which is reflected in the lower agonist affinities obtained. As expected, no decrease in fluorescence intensity was observed in the presence of XAC, meaning that there is no decrease in binding of the probe over time and its binding is specific to the MOR. Emission spectra: excitation at 360 nm, cutoff at 420 nm, scan emission from 430-710 nm at 2 nm steps. Excitation spectra: emission at 700 nm, cutoff at 695 nm, scan excitation from 300-680 nm at 2 nm steps. Compound 3: Emission spectra: excitation at 590 nm, cutoff at 610 nm, scan emission from 620-800 nm at 2 nm steps. Excitation spectra: emission at 700 nm, cutoff at 695 nm, scan excitation from 300-680 nm at 2 nm steps. All measurements were normalized and plotted using GraphPad Prism 6 (GraphPad Software, San Diego, CA). 4R,7R,7aR,12bS,14S )-14-((6-ammoniohexyl)carbamoyl)-9-hydroxy-7-methoxy-3-methyl- 2,3,4,7,7a-hexahydro-7,4a-ethano-4,12-methanobenzofuro[3,2 -e]isoquinolin-3-ium chloride (9) . tert-Butyl- (6-((4R,6S,7R,7aR,12bS) tert-Butyl(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexyl)carbamate (12) . Compound 3 (536 mg, 2.48 mmol) was added to THF (9 mL) and sat. NaHCO3 (15 mL) and left to stir at 0 o C for 10 min.
(3R,6S,7R,7aR,12bS)-6-((6-(3-(6-Amino-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)yl)propanamido)hexyl)carbamoyl)-9-hydroxy-7-methoxy-3-methyl
N-(Ethoxycarbonyl)maleimide (386 mg, 2.28 mmol) dissolved in more THF (6 mL) and then slowly added over 5 min. The mixture was allowed to stir for 15 min, after which time a further 30 mL of THF was added. This mixture was allowed to stir for another 45 min and cool to room temperature.
The mixture was then extracted with EtOAc (3 × 60 mL), washed with brine (120 mL), dried with Na2SO4 and the solvent removed in vacuo. The residual solid was purified by column chromatography (EtOAc) to yield compound 12 as a white solid (89%, 602 mg). 1 H NMR and 13 C NMR spectral data were in agreement with Kobayashi et al. 68 tert-Butyl (6- ((1R,4aS,9aR,10R,10aS,13aR [3,4-h] isoquinolin-2-ium chloride (14) . 
